03:59 AM EST, 11/18/2024 (MT Newswires) -- AbbVie ( ABBV ) said Monday the European Commission has granted marketing authorization for Elahere to treat adult patients with a specific type of platinum-resistant ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

The company said Elahere is the first and only novel therapy approved in the European Union for patients with folate receptor-alpha positive, platinum-resistant ovarian cancer

AbbVie ( ABBV ) is collaborating with Roche Diagnostics on a companion diagnostic test to identify patients who may be eligible for Elahere.

The marketing authorization of Elahere is supported by data from a phase 3 trial, which demonstrated its overall survival benefit with a 33% reduction in the risk of death compared with chemotherapy, AbbVie ( ABBV ) said.